BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28839198)

  • 1. The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis.
    Liu Z; Que S; Zhou L; Zheng S; Romeo S; Mardinoglu A; Valenti L
    Sci Rep; 2017 Aug; 7(1):9273. PubMed ID: 28839198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients.
    Milano M; Aghemo A; Mancina RM; Fischer J; Dongiovanni P; De Nicola S; Fracanzani AL; D'Ambrosio R; Maggioni M; De Francesco R; Fargion S; Berg T; Stickel F; Hampe J; Romeo S; Colombo M; Valenti L
    Hepatology; 2015 Jul; 62(1):111-7. PubMed ID: 25820484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.
    Sagnelli C; Merli M; Uberti-Foppa C; Hasson H; Grandone A; Cirillo G; Salpietro S; Minichini C; Starace M; Messina E; Morelli P; Miraglia Del Giudice E; Lazzarin A; Coppola N; Sagnelli E
    World J Gastroenterol; 2016 Oct; 22(38):8509-8518. PubMed ID: 27784963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.
    Coppola N; Rosa Z; Cirillo G; Stanzione M; Macera M; Boemio A; Grandone A; Pisaturo M; Marrone A; Adinolfi LE; Sagnelli E; Miraglia del Giudice E
    Liver Int; 2015 Aug; 35(8):1959-63. PubMed ID: 25581573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
    Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
    Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C.
    Manchiero C; Nunes AKDS; Magri MC; Dantas BP; Mazza CC; Barone AA; Tengan FM
    BMC Infect Dis; 2017 Dec; 17(1):780. PubMed ID: 29258449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
    Eslam M; Mangia A; Berg T; Chan HL; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MA; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J;
    Hepatology; 2016 Jul; 64(1):34-46. PubMed ID: 26822232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
    Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
    Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children.
    Grandone A; Cozzolino D; Marzuillo P; Cirillo G; Di Sessa A; Ruggiero L; Di Palma MR; Perrone L; Miraglia Del Giudice E
    Pediatr Obes; 2016 Apr; 11(2):115-9. PubMed ID: 25893821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
    Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
    J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.
    Dongiovanni P; Petta S; Maglio C; Fracanzani AL; Pipitone R; Mozzi E; Motta BM; Kaminska D; Rametta R; Grimaudo S; Pelusi S; Montalcini T; Alisi A; Maggioni M; Kärjä V; Borén J; Käkelä P; Di Marco V; Xing C; Nobili V; Dallapiccola B; Craxi A; Pihlajamäki J; Fargion S; Sjöström L; Carlsson LM; Romeo S; Valenti L
    Hepatology; 2015 Feb; 61(2):506-14. PubMed ID: 25251399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study.
    Rauff B; Alzahrani B; Chudhary SA; Nasir B; Mahmood S; Bhinder MA; Faheem M; Amar A
    BMC Gastroenterol; 2022 Aug; 22(1):401. PubMed ID: 36028802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection.
    Hui JM; Kench J; Farrell GC; Lin R; Samarasinghe D; Liddle C; Byth K; George J
    J Gastroenterol Hepatol; 2002 Aug; 17(8):873-81. PubMed ID: 12164963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Genetics of Clinical Liver Diseases: Insight into the
    Zhang X; Liu S; Dong Q; Xin Y; Xuan S
    J Clin Transl Hepatol; 2018 Sep; 6(3):326-331. PubMed ID: 30271746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
    Luukkonen PK; Zhou Y; Nidhina Haridas PA; Dwivedi OP; Hyötyläinen T; Ali A; Juuti A; Leivonen M; Tukiainen T; Ahonen L; Scott E; Palmer JM; Arola J; Orho-Melander M; Vikman P; Anstee QM; Olkkonen VM; Orešič M; Groop L; Yki-Järvinen H
    J Hepatol; 2017 Jul; 67(1):128-136. PubMed ID: 28235613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of CXCL9-11 gene polymorphisms in liver fibrosis among patients with chronic hepatitis C.
    Magri MC; Alvarez MSM; Iogi AA; Alves GM; Manchiero C; Dantas BP; Prata TVG; Nunes AKDS; Tengan FM
    Pathog Dis; 2021 Mar; 79(3):. PubMed ID: 33476381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.
    Newberry EP; Hall Z; Xie Y; Molitor EA; Bayguinov PO; Strout GW; Fitzpatrick JAJ; Brunt EM; Griffin JL; Davidson NO
    Hepatology; 2021 Sep; 74(3):1203-1219. PubMed ID: 33638902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic disorders induced by PNPLA3 and TM6SF2 gene variants affect chronic kidney disease in patients infected with non-genotype 3 hepatitis C virus.
    Liu J; Qi W; Wang S; Zhang Y; Wang X; Sun D; Xu Y; Shi J; Duan H; Zhang Q; Wang H; Wang J
    Lipids Health Dis; 2023 Jul; 22(1):91. PubMed ID: 37400794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of PNPLA3 rs738409 variant (I148 M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C.
    Yasui K; Kawaguchi T; Shima T; Mitsuyoshi H; Seki K; Sendo R; Mizuno M; Itoh Y; Matsuda F; Okanoue T
    J Gastroenterol; 2015 Aug; 50(8):887-93. PubMed ID: 25543233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C.
    Valenti L; Rumi M; Galmozzi E; Aghemo A; Del Menico B; De Nicola S; Dongiovanni P; Maggioni M; Fracanzani AL; Rametta R; Colombo M; Fargion S
    Hepatology; 2011 Mar; 53(3):791-9. PubMed ID: 21319195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.